Form 4 Nuvalent Inc For: 15 July
- Investing.com
Precision Medicine | The company's focused strategy targeting genetically defined patient populations aligns with industry trends toward personalized cancer therapies, addressing significant unmet needs in specialized oncology segments |
Regulatory Momentum | Discover how Nuvalent's completed rolling NDA submission for ROS1-positive patients and anticipated pivotal data by year-end 2025 create near-term catalysts for potential market authorization |
Analyst Outlook | Price targets range from $116 to $189 with strong buy consensus, reflecting confidence in the therapeutic approach despite projected losses of approximately $5.61-$5.75 per share through fiscal years |
Clinical Excellence | Neladalkib demonstrates exceptional durability of response in ALK-positive non-small cell lung cancer, exceeding initial expectations and positioning as a competitive differentiator in targeted oncology treatments |
Metrics to compare | NUVL | Peers Peers - average of corresponding metrics from companies closely matching NUVL: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipNUVLPeersSector |
|---|---|---|---|---|
P/E Ratio | −21.9x | 0.0x | −0.4x | |
PEG Ratio | 0.59 | 0.00 | 0.00 | |
Price / Book | 8.4x | 0.0x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.1x | |
Upside (Analyst Target) | 0.0% | 0.0% | 48.2% | |
Fair Value Upside | Unlock | 0.0% | 5.8% | Unlock |